- Home
- IOR vs IMMX Comparison
IOR vs IMMX Comparison
Compare IOR & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- IMMX
- Stock Information
- Founded
- IOR 1984
- IMMX 2014
- Country
- IOR United States
- IMMX United States
- Employees
- IOR N/A
- IMMX N/A
- Industry
- IOR Real Estate Investment Trusts
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- IOR Real Estate
- IMMX Health Care
- Exchange
- IOR Nasdaq
- IMMX Nasdaq
- Market Cap
- IOR 72.8M
- IMMX 65.5M
- IPO Year
- IOR N/A
- IMMX 2021
- Fundamental
- Price
- IOR $17.75
- IMMX $2.47
- Analyst Decision
- IOR
- IMMX Strong Buy
- Analyst Count
- IOR 0
- IMMX 1
- Target Price
- IOR N/A
- IMMX $8.00
- AVG Volume (30 Days)
- IOR 126.0
- IMMX 221.4K
- Earning Date
- IOR 11-06-2025
- IMMX 11-11-2025
- Dividend Yield
- IOR N/A
- IMMX N/A
- EPS Growth
- IOR N/A
- IMMX N/A
- EPS
- IOR 1.06
- IMMX N/A
- Revenue
- IOR N/A
- IMMX N/A
- Revenue This Year
- IOR N/A
- IMMX N/A
- Revenue Next Year
- IOR N/A
- IMMX N/A
- P/E Ratio
- IOR $17.04
- IMMX N/A
- Revenue Growth
- IOR N/A
- IMMX N/A
- 52 Week Low
- IOR $16.01
- IMMX $1.34
- 52 Week High
- IOR $19.69
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- IOR 43.18
- IMMX 67.32
- Support Level
- IOR $17.75
- IMMX $1.94
- Resistance Level
- IOR $19.00
- IMMX $2.13
- Average True Range (ATR)
- IOR 0.08
- IMMX 0.16
- MACD
- IOR -0.04
- IMMX 0.05
- Stochastic Oscillator
- IOR 0.00
- IMMX 99.45
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.